BioSpace News Archive

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the fourth quarter and full year ended December 31, 2022.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant Association / Harvard Stem Cell Institute / Juvenile Diabetes Research Fund Summit, to be held from April 24-25, 2023 in Cambridge, Massachusetts.

Photocure ASA announces its participation in the congress, and two abstract presentations at the European Association of Urology congress in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy in Bladder Cancer management.

So-Young International Inc. announced that it will report its financial results for the fourth quarter and full year ended December 31, 2022, before U.S. markets open on March 21, 2023.

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2022.

TScan Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1 umbrella trial of TSC-100 and TSC-101 targeting minor histocompatibility antigens (MiHA) HA-1 and HA-2.

ASLAN Pharmaceuticals today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan.

XORTX Therapeutics Inc. is pleased to announce submission of a Type D meeting request to the US Food and Drug Administration (“FDA”).

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022.